REKA Stock Overview
Engages in the manufacture, marketing, sale, and distribution of prescription and OTC drugs, dermo-cosmetics, vitamins, and nutritional supplements in Israel. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Rekah Pharmaceutical Industry Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₪13.92 |
| 52 Week High | ₪16.01 |
| 52 Week Low | ₪11.67 |
| Beta | 0.049 |
| 1 Month Change | -2.11% |
| 3 Month Change | 5.78% |
| 1 Year Change | -9.02% |
| 3 Year Change | -39.21% |
| 5 Year Change | -25.40% |
| Change since IPO | -96.02% |
Recent News & Updates
Rekah Pharmaceutical Industry Ltd.'s (TLV:REKA) Shares Climb 30% But Its Business Is Yet to Catch Up
Jul 11
Here's Why Rekah Pharmaceutical Industry (TLV:REKA) Has A Meaningful Debt Burden
Jul 05Recent updates
Rekah Pharmaceutical Industry Ltd.'s (TLV:REKA) Shares Climb 30% But Its Business Is Yet to Catch Up
Jul 11Here's Why Rekah Pharmaceutical Industry (TLV:REKA) Has A Meaningful Debt Burden
Jul 05Here's Why Rekah Pharmaceutical Industry Ltd.'s (TLV:REKA) CEO May Not Expect A Pay Rise This Year
Dec 14Rekah Pharmaceutical Industry (TLV:REKA) Has A Somewhat Strained Balance Sheet
Sep 12Estimating The Fair Value Of Rekah Pharmaceutical Industry Ltd. (TLV:REKA)
Jul 19Rekah Pharmaceutical Industry's (TLV:REKA) Problems Go Beyond Weak Profit
Apr 13We Think Rekah Pharmaceutical Industry (TLV:REKA) Is Taking Some Risk With Its Debt
May 12Here's Why I Think Rekah Pharmaceutical Industry (TLV:REKA) Might Deserve Your Attention Today
Apr 09Does Rekah Pharmaceutical Industry's (TLV:REKA) Share Price Gain of 50% Match Its Business Performance?
Mar 12Rekah Pharmaceutical Industry Ltd.'s (TLV:REKA) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?
Feb 19
Is Rekah Pharmaceutical Industry (TLV:REKA) Using Too Much Debt?
Jan 29Here's Why I Think Rekah Pharmaceutical Industry (TLV:REKA) Is An Interesting Stock
Jan 08How Is Rekah Pharmaceutical Industry's (TLV:REKA) CEO Paid Relative To Peers?
Dec 18Investors Who Bought Rekah Pharmaceutical Industry (TLV:REKA) Shares Five Years Ago Are Now Up 33%
Nov 30Shareholder Returns
| REKA | IL Pharmaceuticals | IL Market | |
|---|---|---|---|
| 7D | 0.3% | 0.9% | -0.5% |
| 1Y | -9.0% | -12.2% | 23.0% |
Return vs Industry: REKA exceeded the IL Pharmaceuticals industry which returned -12.2% over the past year.
Return vs Market: REKA underperformed the IL Market which returned 23% over the past year.
Price Volatility
| REKA volatility | |
|---|---|
| REKA Average Weekly Movement | 4.6% |
| Pharmaceuticals Industry Average Movement | 6.2% |
| Market Average Movement | 4.2% |
| 10% most volatile stocks in IL Market | 8.0% |
| 10% least volatile stocks in IL Market | 3.0% |
Stable Share Price: REKA has not had significant price volatility in the past 3 months compared to the IL market.
Volatility Over Time: REKA's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1941 | 427 | Mordechai Elgrabli | www.rekah.co.il |
Rekah Pharmaceutical Industry Ltd. engages in the manufacture, marketing, sale, and distribution of prescription and OTC drugs, dermo-cosmetics, vitamins, and nutritional supplements in Israel. The company offers steroid tablets; antibiotics, including penicillin and cephalosporin; drops and ointments to treat allergies, infections, and dryness of the eyes; baby products; and dermatological preparations. Its portfolio of products comprise approximately 280 drugs used in various medical fields.
Rekah Pharmaceutical Industry Ltd. Fundamentals Summary
| REKA fundamental statistics | |
|---|---|
| Market cap | ₪158.89m |
| Earnings (TTM) | ₪7.63m |
| Revenue (TTM) | ₪331.60m |
20.8x
P/E Ratio0.5x
P/S RatioIs REKA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| REKA income statement (TTM) | |
|---|---|
| Revenue | ₪331.60m |
| Cost of Revenue | ₪258.85m |
| Gross Profit | ₪72.74m |
| Other Expenses | ₪65.12m |
| Earnings | ₪7.63m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.67 |
| Gross Margin | 21.94% |
| Net Profit Margin | 2.30% |
| Debt/Equity Ratio | 63.7% |
How did REKA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 03:05 |
| End of Day Share Price | 2024/12/19 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Rekah Pharmaceutical Industry Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|